- Home
- MPW vs AKRO Comparison
MPW vs AKRO Comparison
Compare MPW & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- AKRO
- Stock Information
- Founded
- MPW 2003
- AKRO 2017
- Country
- MPW United States
- AKRO United States
- Employees
- MPW N/A
- AKRO N/A
- Industry
- MPW Real Estate Investment Trusts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- AKRO Health Care
- Exchange
- MPW Nasdaq
- AKRO Nasdaq
- Market Cap
- MPW 3.3B
- AKRO 2.8B
- IPO Year
- MPW 2005
- AKRO 2019
- Fundamental
- Price
- MPW $5.24
- AKRO $39.85
- Analyst Decision
- MPW Hold
- AKRO Strong Buy
- Analyst Count
- MPW 6
- AKRO 9
- Target Price
- MPW $5.75
- AKRO $76.29
- AVG Volume (30 Days)
- MPW 8.8M
- AKRO 1.1M
- Earning Date
- MPW 05-01-2025
- AKRO 05-16-2025
- Dividend Yield
- MPW 6.09%
- AKRO N/A
- EPS Growth
- MPW N/A
- AKRO N/A
- EPS
- MPW N/A
- AKRO N/A
- Revenue
- MPW $994,615,000.00
- AKRO N/A
- Revenue This Year
- MPW N/A
- AKRO N/A
- Revenue Next Year
- MPW $5.07
- AKRO N/A
- P/E Ratio
- MPW N/A
- AKRO N/A
- Revenue Growth
- MPW 23.51
- AKRO N/A
- 52 Week Low
- MPW $3.51
- AKRO $17.86
- 52 Week High
- MPW $6.55
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MPW 46.18
- AKRO 44.56
- Support Level
- MPW $5.00
- AKRO $41.60
- Resistance Level
- MPW $5.85
- AKRO $46.47
- Average True Range (ATR)
- MPW 0.20
- AKRO 2.26
- MACD
- MPW -0.01
- AKRO 0.08
- Stochastic Oscillator
- MPW 28.24
- AKRO 21.84
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.